ROCKVILLE, Md.--(BUSINESS WIRE)--Supernus Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga™. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Epliga for the adjunctive treatment of refractory partial onset seizures in patients with epilepsy.
